The findings from two randomized placebo controlled trials, STOP-CLI, testing JVS-100 in patients with critical limb ischemia, and STOP-HF, testing JVS-100 in patients with advanced heart failure, highlight the safety and potential efficacy of Juventas' novel gene therapy strategy.
http://ift.tt/10ZjEAS
http://ift.tt/10ZjEAS
No comments:
Post a Comment